



Published in final edited form as:

*AIDS Behav.* 2015 July ; 19(7): 1129–1140. doi:10.1007/s10461-014-0860-6.

## Female Condom Use among Female University Students in KwaZulu-Natal, South Africa: Results of a Randomized Behavioral Trial

Joanne E. Mantell<sup>1</sup>, Jennifer A. Smit<sup>2,3</sup>, Theresa M. Exner<sup>1</sup>, Zonke Mabude<sup>2</sup>, Susie Hoffman<sup>1,4</sup>, Mags Beksinska<sup>2</sup>, Elizabeth A. Kelvin<sup>1,5</sup>, Claudia Ngoloyi<sup>2</sup>, Cheng-Shiun Leu<sup>1,6</sup>, and Zena A. Stein<sup>1,7</sup>

<sup>1</sup> HIV Center for Clinical and Behavioral Studies, New York State Psychiatric Institute and Columbia University New York, NY 10032, USA

<sup>2</sup>MatCHRResearch [Maternal, Adolescent and Child Health Research], Department of Obstetrics and Gynaecology, Faculty of Health Sciences, University of the Witwatersrand Westville, 3629 Durban, South Africa

<sup>3</sup>School of Pharmacy and Pharmacology, Faculty of Health Sciences, University of KwaZulu-Natal Durban, South Africa

<sup>4</sup>Mailman School of Public Health at Columbia University, Department of Epidemiology New York, NY 10032

<sup>5</sup> City University of New York School of Public Health, Hunter College, Epidemiology and Biostatistics Program New York, NY 10035, USA

<sup>6</sup>Mailman School of Public Health at Columbia University, Department of Biostatistics New York, NY 10032, USA

<sup>7</sup>GH Sergievsky Center, Joseph Mailman School of Public Health, Columbia University New York, NY 10032, USA

### Abstract

Relatively few interventions have tested the efficacy of female condom promotion either alone or in combination with other barrier methods. We evaluated the efficacy of a *two-session (enhanced) cognitive-behavioral* intervention (EI) (n=147) against a one-session control (minimal) educational intervention (MI) (n=149) to promote female condom (FC) use among female students aged 18-28 at a South African university. We assessed change from baseline to 2.5 and 5 months in number of vaginal intercourse occasions unprotected by male or female condoms in EI vs. MI using

---

**Corresponding Author** Joanne E. Mantell HIV Center for Clinical and Behavioral Studies, New York State Psychiatric Institute and Columbia University 1051 Riverside Drive, Unit 15 New York, NY 10032, USA Telephone: (646) 774-6951 Fax: (212) 982-1030 jem57@columbia.edu; jmantell@verizon.net.

Author contributions. JEM, JAS, MB, TME, SH, ZAS designed and planned the study. JAS, ZM, and CN led study implementation and data collection. C-SL conducted the statistical analysis and JEM, JAS, TME, SH, MB, EAK were involved in interpretation of the data. JEM with input from TME, JAS, MB, SH, C-SL, EAK wrote the first draft of the manuscript. All authors contributed and reviewed all drafts of the manuscript.

Conflicts of interest

There are no conflicts of interest.

generalized linear models with a log link function and GEE. Both groups reported significant reductions in number of unprotected vaginal intercourse occasions from baseline to each follow-up, with no significant difference between the two-session and single-session intervention. Introduction of a brief group-based *MI* FC promotion intervention with FC access holds promise for delivery in clinics and other community venues.

## Keywords

Female condom; South Africa; University students; HIV; Pregnancy

---

## Introduction

The Reproductive Health Supplies Coalition and UN Commission on Life-Saving Commodities for Women and Children identified the female condom (FC) as one of several overlooked and under-used reproductive health technologies having the potential to expand choice in family planning and HIV/STI prevention programs, add value to the method mix, and respond to the needs of diverse clients [1, 2]. The FC has also been cited as an essential strategy for pregnancy and HIV/STI prevention by the World Health Organization [3]. A number of studies [4-7] and one review [8] suggest that concurrent availability of female and male condoms results in higher rates of protected sex compared with only male condom availability. The FC affords women greater control over negotiating protection of their health [9].

The FC as a tool for reducing HIV/STI and pregnancy risks has not been fully recognized, resulting in inadequate marketing [2] and underfunding of programs [10, 11]. Despite increased FC distribution globally (from 25 million units in 2007 to 50 million units in 2010 [12], and in 2012, 60 million units [13]), distribution still lags behind that of the male condom [14]. The average unit cost is about US \$0.57 for FC compared to \$0.03 for a male latex condom [2].

FC acceptability and uptake may increase, however, now that there are several new FCs using alternate designs and materials and others on the horizon [15-17]. Coupled with new product development have been intensified strategic campaigns of several international groups, including the United Nations Population Fund's Global Female Condom Initiative, which provides support to at least 23 countries to scale up FC programming and the Universal Access to Female Condoms Joint Programme, through the provision of FCs and educational programs targeting men, youth and women at risk. The governments of a number of countries, including South Africa, Brazil and India, are committed to promoting the FC, reflected in their large-scale purchase of FCs for public-sector distribution [18]. Programming support is critical as it has been documented that funding for the product, without investment in effective and comprehensive programming, can lead to stock-outs, lack of access and limited availability [19].

Methods that women can use such as the female condom are an important prevention option to enable women to protect themselves, especially in regions such as sub-Saharan Africa, where heterosexual transmission is the predominant mode of HIV transmission. South Africa

has a generalized HIV epidemic with an HIV prevalence of 12.2% and the largest HIV-positive population in the world (6.4 million persons) [20]. HIV prevalence is 14.4% among South African women, and among women aged 20-24, 17.4% compared to 5.1% among men of the same age, peaking at 36.0% among women aged 30-34% and at 28.8% among men aged 35-39 [20]. The HIV incidence rate among female youth aged 15-24 is more than four times higher than the incidence rate found in males in this age group (2.5% vs. 0.6%) and [20], and black African females aged 20-34 years have the highest incidence of HIV at (4.5%) compared to other population groups. Unintended pregnancy rates also are high, with one study estimating 66% of young women having had an unintended pregnancy [21], despite a 65% contraceptive use prevalence [22].

South Africa has highly-supportive government policies for the FC [23] and one of the largest, best-established, government-funded, public-sector FC programs world-wide, with robust distribution in clinic and community venues [15, 17]. In 2010, the South African government procured 5.1 million FC units in 2010 [14], and for 2012, projected procurement more than doubled to 11 million FCs [24]. This creates a receptive environment for testing interventions to promote the FC. However, a 2008 population-based household survey found that only 7.2% of sexually active women and 6.0% of men reported ever having used the FC [25]. The target group for this intervention, university students in South Africa, is an understudied population at risk for HIV/STIs, with HIV prevalence at 3.8% among sexually active students. In KwaZulu-Natal, prevalence was 6.1% in students overall and 8.7% in African Black students in a survey of 22 institutions of higher learning in 2008-2009 [26]. To our knowledge, there are no studies in South Africa that have tested the efficacy of an intervention that promoted the FC.

Relatively few intervention studies have tested the efficacy of FC promotion either alone [27-35], or in combination with other barrier methods [4, 5, 36-38], and few have been conducted in sub-Saharan Africa [6, 27, 31, 35]; none have been conducted with university students. We compared the efficacy of a two-session group-delivered *Enhanced Intervention (EI)*, which included didactic information delivered in the *MI*, in addition to behavioral rehearsal of FC use, partner negotiation, and opportunity to practice these skills and problem-solve in the second session, against a one-session control information-only, group-delivered (*MI*). We assessed whether the *EI* compared to the *MI* resulted in (1) a greater decrease in the proportion of vaginal sex acts unprotected by condoms, (2) a greater increase in the proportion of vaginal sex acts protected by FCs, and (3) a greater number of female condoms used.

## Methods

### Participants and Procedures

Between March 2008 and October 2009 we recruited women on the campus of a higher education institution in KwaZulu-Natal, South Africa, using outreach at campus sites where students congregated. Women were eligible for study participation if they met the following criteria: 18 years or older; full-time students; self-reported HIV-negative or unknown serostatus; not pregnant or wanting to become pregnant in the next nine months; reported condom-unprotected vaginal intercourse in the past two months; capacity to complete

informed consent and be interviewed; willing to have assessments and interventions audio-recorded. First-year, first semester students were excluded because of high drop-out rates.

We approached students to inform them about the study and determine whether they might be interested in volunteering to participate. Following screening, eligible students completed written informed consent and were scheduled for a baseline interview. After the baseline interview, participants were invited to attend an intervention randomization meeting within the following three weeks, where they were randomly assigned, in blocks of two, to either the one-session *MI* (N=149) or two-session *EI* (N=147); they participated in their assigned intervention on the day of randomization. Those randomized to the two-session intervention attended the second session approximately three weeks after the first. All study staff, other than the intervention facilitators, were blinded to intervention condition. Follow-up assessments were conducted at 2.5 and 5 months after completion of the intervention. Participants received the ZAR equivalent of \$4 for the baseline assessment, \$10 for the first follow-up assessment, and \$15 for the second follow-up interview. The Institutional Review Board of the New York State Psychiatric Institute-Columbia University Department of Psychiatry and Research Ethics Committees at two South African universities, including the institution where the study was conducted, approved the study.

### Description of Interventions

The enhanced and minimal (control) interventions, developed and refined by the US-South African Research team, including Student Health Service and Counseling Centre staff, are described below.

**Minimal Intervention**—The one-session, 1-1.5 hour *MI* focused on HIV/STI transmission and safer sex practices; personal vulnerability to disease and pregnancy; ways to address these risks and problems encountered; importance of barrier method use and universal safer sex precautions; FC's ability to prevent both HIV/STIs and pregnancy; how to use, insert, remove and dispose of FCs; and comparison of the use-effectiveness and other features of the male and female condom. In addition, a brief review of the female reproductive system was provided, and FC insertion was demonstrated on a pelvic model, but insertion practice by participants on the model was not done. The facilitators elicited perceptions about the FC and anticipated problems with use. The intervention also sensitized women to the potential for partner abuse and provided instruction on how to assess signs of potential abuse and presented strategies to minimize the risk. Women were cautioned about possible dangers of initiating male or female condom use in the presence of these signs, and were provided with pamphlets listing referral sources.

**Enhanced Intervention**—The two-session, 4-5 hour *EI*, grounded in Social Learning Theory [39, 40], included the same information as the one-session *MI*, but also covered partner negotiation, FC insertion skills, and personal goal-setting to achieve HIV/pregnancy prevention. The *EI* specifically addressed (1) obtaining and maintaining a condom supply; (2) having condoms for use when needed; (3) negotiating condom use with partners in a way likely to succeed; (4) overcoming objections, resistance, refusal and violence that might be encountered; (5) inserting and using female and male condoms correctly; (6) using cognitive

restructuring, behavioral rehearsal, and structured practice with feedback strategies;(7) increasing positive expectancies for FC use by fostering positive peer norms; and (8) providing encouragement and reinforcement through social support.

Women in both groups were given a supply of 10 FCs and 10 male condoms and had access to free male and female condoms through the Campus Health Service. All sessions were conducted in English, but *isiZulu* was spoken when issues needed further clarification. The interventions were facilitated by study staff with nursing or social science backgrounds trained and experienced in group facilitation. Each of the interventions was delivered by a different interventionist to avoid contamination across the arms. The quality of intervention delivery was monitored by the study intervention director and was considered to be similar. In both groups, facilitators were assisted by trained student peer educators who led many of the group exercises.

## Measures

**Primary and secondary outcomes**—The *primary study outcome* was the number of vaginal intercourse occasions unprotected by either male or female condoms in the past 2.5 months across all partners. Unprotected occasions, in contrast to percent protected occasions, is an indicator of overall public health impact since the raw number of potential viral exposures is more clearly interpretable in terms of infection risk than percent condom use, which can mask different levels of risk among those reporting the same rate of use (e.g., two persons reporting 50% condom use who have 100 or 10 sex occasions would have 50 and 5 unprotected occasions, respectively). *Secondary outcomes* included the (1) number of FCs used; (2) proportion of FC-protected vaginal intercourse occasions across all partners; (3) proportion of vaginal intercourse occasions protected by either a female or male condom; and (4) male/female condom use at last sex occasion.

**Other sexual risk-related outcomes**—Perceived susceptibility to HIV and unintended pregnancy were measured by single items asking how great the participant thought her chances were of getting infected with HIV or getting pregnant unintentionally in the next six months, with responses on a four-point Likert scale ranging from *no risk at all* to *great risk*. Single items were used to assess participants' overall attitude toward the male condom and to the FC – *How do you feel about using the male condom? the female condom?* Responses were on a five-point Likert scale ranging from *extremely positive* to *extremely negative*. Participants used the same metrics to evaluate their main partner's perceived attitude toward male and female condom use. Intention to use female condoms was assessed by a single item about the likelihood of using a female condom during sex. Responses were on a four-point Likert scale ranging from *very unlikely* to *very likely*. Peer norms for condom use were measured by an eight-item scale ( $\alpha=0.71$ ) developed for this study with items that assessed what participants thought the women they knew were doing regarding condom use (e.g., Women I know will say “no” to sex if a partner won't use condoms). Response categories were on a four-point Likert scale, ranging from *strongly disagree* to *strongly agree*. Condom self-efficacy, which assessed participants' confidence in using condoms, was adapted from a measure used in Project FIO [41, 42] and included items suggested by pilot data as relevant to the South African context. It was measured by a 13-item scale ( $\alpha=0.78$ ) (e.g., How sure

are you that you could insist on using a condom if a main partner threatens to leave you if he has to use a condom?). Responses ranged on a four-point Likert scale from *very unsure* to *very sure*. Gender norms for women's and men's sexual behavior were measured with a nine-item scale tapping male dominant sex roles ( $\alpha=0.65$ ) originally developed on a sample of young South African adults[43] (e.g., *Men cannot live with just one girlfriend*). Response categories were on a four-point Likert scale, ranging from *strongly disagree* to *strongly agree*. Hormonal contraceptive use was measured by whether participants used the pill, injectable, or emergency contraception, with *yes*, *no* responses. Total number of sex occasions was assessed across all partners.

### Statistical Analysis

Descriptive statistics were generated overall and by group for demographic variables at baseline, as well as for sexual behavior and pertinent knowledge, normative and attitudinal factors at baseline and follow-ups. Baseline differences were evaluated using t-tests for continuous and chi-squared test for categorical variables. The *a priori* primary analysis, following intent-to-treat principles, compared the *EI* to *MI* in terms of the mean change from baseline to 2.5 months post-intervention (FU1) in total number of vaginal intercourse occasions unprotected by male or female condoms. We used generalized linear models (GLM) with a log link function. The model included the group indicator for *EI* (vs. *MI*), the indicator for time (FU1 vs. baseline), and the interaction of the two indicators. The regression coefficient corresponding to the group-by-time interaction term estimates the logarithm of the ratio of the two study group population rate ratios and thus represents the effect of the intervention on change in unprotected sex occasions. The rate ratio is defined as the mean number of vaginal intercourse occasions unprotected by either male or female condoms at 2.5 months divided by the mean number of vaginal intercourse occasions unprotected by either male or female condoms at baseline. We employed generalized estimating equations (GEE) to account for the effect of intra-cluster correlations introduced by multiple assessments on the same participant. An over-dispersion parameter was used to account for the between-subject heterogeneity for Poisson regression analysis. Rubin's [44] multiple imputation method with 11 repeated imputations was employed to impute the missing endpoint for conducting the intent-to-treat analysis.

In secondary analyses, we evaluated longer-term intervention effects on reducing unprotected vaginal sex occasions, comparing the *EI* to the *MI* on the change from baseline to five-month follow-up (FU2). We also compared the two groups on other sexual risk-related secondary outcomes, such as condom use self-efficacy and peer norms for condom use. We used GLM with identity, logit, and log link function for continuous, dichotomous, and count variables respectively. As with the primary analysis, GEE methodology was employed to account for the correlation due to repeated measures and an over-dispersion parameter was used to account for the between subject heterogeneity when appropriate. Data were cleaned and processed in SPSS (Chicago, IL) version 20 and regression models run in SAS version 9.3 (IBM, Cary, NC).



## Results

### Participant flow and characteristics of the randomized sample

Figure 1 shows the participant flow from recruitment to five months post-intervention. Of the 5,773 women screened, 628 (11.0%) were eligible for study participation, 491 (78.2% of those eligible) completed the baseline interview, and 296 (60.3% of those completing baseline) were randomized. Of the randomized participants, 147 were assigned to the *EI* and 149 to the *MI*. All women who were randomized to the *MI* attended the intervention since the intervention comprised one session on the same day as randomization. Of the 147 women assigned to the *EI*, all attended the first session and 118 (80.3%) attended both sessions. Overall, 84.1% of all participants completed the 2.5-month post-intervention interview (83.0% of *EI* and 85.2% of *MI*;  $p=0.60$ ) and 78.7% completed the 5-month post-intervention interview (77.6% of *EI* and 79.9% of *MI*;  $p=0.63$ ).

Participants were on average 20.1 years of age ( $SD=1.9$ ). All participants were Black African. Most (95.3%) currently had a main partner, who on average was 3.5 years older than the participant ( $SD=2.8$ ). Many (44.3%) believed their partner to be at risk for HIV/STI, with 8.0% reporting that their partner had an STI in the prior year. Participants had on average 2.6 partners ( $SD=2.3$ ) in their lifetimes (Table 1). At baseline, only 12 women (4.7%) reported they had ever used a FC, whereas most had partners who had used male condoms (97.6%). There were no significant differences by intervention condition in any of the demographic, attitudinal, HIV/STI, pregnancy, contraception, sexual behavior, or condom use variables.

### Trial results

Both groups reported significant reductions in the number of vaginal intercourse occasions unprotected by either male or female condoms from baseline to the 2.5- and 5-month follow-up (Table 2). Specifically, at the 2.5-months follow-up, the number of unprotected vaginal sex acts was 0.53 times lower in the *MI* ( $p=0.02$ ) group and 0.41 times lower in the *EI* group ( $p<0.0001$ ) relative to baseline; at the 5-month follow-up, it was 0.39 times lower in the *MI* group ( $p<0.0001$ ) and 0.40 times lower in the *EI* ( $p<0.0001$ ) group. (Table 2) The change in number of unprotected vaginal sex acts over time did not differ significantly by intervention group (interaction  $p$ -value=0.44 at 2.5 months and 0.97 at 5 months). (Data not shown)

The same pattern of results was found for secondary sexual behavior outcomes. Number of FCs used increased 135.6 times between baseline and 2.5-month follow-up among the *MI* group ( $p<0.0001$ ) and 16.8 times in the *EI* group ( $p<0.001$ ), although this group difference was not statistically significant ( $p$ -value for interaction between time and intervention=0.06), nor were there significant differences between groups on any of the other sexual behavior variables. The number of FCs used between baseline and 5-month follow-up increased 58.0 times in the *MI* group ( $p<0.001$ ) and 12.7 times in the *EI* ( $p<0.01$ ); ( $p=0.18$  for difference in the change over time by group). Additionally, the percent of vaginal intercourse occasions protected by a FC increased in the *MI* group by 0.15 from baseline to 2.5-months ( $p<0.0001$ ) and by 0.08 from baseline to 5-month follow-up ( $p<0.0001$ ) ( $p=0.46$  for difference in the change over time by group); and in the *EI* group by 0.17 from baseline to 2.5 months

( $p < 0.0001$ ) and 0.11 from baseline to 5 months ( $p < 0.0001$ ) ( $p = 0.18$  for difference in the change over time by group). A similar pattern emerged for the percent of vaginal intercourse occasions protected by either a female or a male condom. Compared to baseline, the odds of condom use (male or female) at last sex act was 5.0 times higher at 2.5-month follow-up ( $p < 0.0001$ ) and 3.1 times higher 5-month follow-up ( $p < 0.0001$ ) in the *MI* group and 4.4 times higher at 2.5 months ( $p < 0.0001$ ) ( $p = 0.74$  for difference in the change over time by group); and 5.9 times higher at 5 months ( $p < 0.0001$ ) in the *EI* group ( $p = 0.12$  for difference in the change over time by group). Use of hormonal contraceptives did not change significantly over time in either group; number of vaginal sex acts decreased significantly between baseline and 5-month follow-up in the *MI* but not in the *EI* group (Table 2). However, change in number of vaginal sex acts over time by group did not account for the finding of no differences in outcomes between the two intervention conditions (data not shown).

### Changes in Other Secondary Outcomes over Time

As shown in Table 3, participants in both groups had a lower perception of their risk for unintended pregnancy and for HIV infection at follow-up. The decrease in unintended pregnancy risk perception at 5-months follow-up was significantly greater in the *MI* group (decrease of 0.42,  $p < 0.001$ ) compared to the *EI* group (decrease of 0.16,  $p = 0.11$ ) (interaction  $p = 0.04$ ).

Furthermore, participants in both groups had more positive feelings about male and female condom use and believed that their partners had more positive attitudes as well at each follow-up interview compared to baseline (Table 4). Both groups reported more positive peer norms for condom use at each follow-up, with those in the *EI* group reporting significantly greater increases relative to the *MI* at the 2.5 month follow-up (interaction  $p = 0.04$ ). As shown in Table 5, participants in both groups reported greater intention to use FCs in the future and increased self-efficacy for condom use at follow-up, although they did not differ with respect to each other.

## Discussion

We conducted an RCT comparing two HIV prevention interventions designed to promote FC use among women attending a South African university using a theory-driven model. Our main and secondary hypotheses were not supported in that women in the *EI* did not do better than women in the *MI*. Our findings suggest that both the *EI* and *MI* resulted in a decrease in sexual risk behavior among women at 2.5 and 5 months relative to baseline. Unprotected sex due to using a male or female condom was reduced, and FC-protected sex and number of FCs used increased over this time period.

The lack of difference between the minimal and enhanced interventions could possibly be because messages delivered in the *MI* were more easily retained by participants in the shorter, more focused *MI*, thus counterbalancing the effect of the enhancements in the *EI*. The need to attend only one session also may have been more feasible for the students to accommodate within their busy academic timetable. Assessment itself has been shown to affect sexual risk-reduction (e.g., [45]), and the cumulative effect of *MI* plus assessment may have been equivalent to *EI*. Participants in both interventions may have reduced unprotected



sex because of exposure to the intensive condom promotion that has taken place in South Africa and the greater availability of FCs in public sector clinics and in non-governmental organizations. FC distribution may have played a critical role in observed increased safer sex as well, since participants in both arms left the interventions with 10 FCs in hand. An increase in FC use in both conditions also could occur independent of the intervention if there were co-temporal increases in FC use in the general population of students on campus. However, evidence from two campus surveys we conducted at this higher education institution in 2008, at the time of the intervention, and two years later in 2010, does not support this idea. Among women who reported ever having had vaginal sex, we found a decrease from 4.7% of women who ever used the FC (21/333) in 2008 to 2.7% (11/324) who reported having used it in 2010 [46, 47].

Facilitators in the *MI* as well as *EI* were encouraged to be champions of „their’ intervention, and thus the passionate delivery of the *MI* may have had a role in the equivalence of the two interventions. Perhaps a key to success in both groups lies in having female condoms on hand as a way to introduce discussion of safer sex with partners with whom they were clearly, at baseline, engaging in risky sex.

It is promising that both interventions showed significant reductions in unprotected sex and increases in the proportion of FC-protected sex at 5 months post-intervention, as well as more immediate effects, as a number of studies have found shorter-term (3 months) intervention effects [28-30, 36]. Nevertheless, further study is needed to investigate whether the intervention actually contributed to such improvement over time, given that the study did not include an assessment-only group in this comparison.

With competing non-health promotion activities on campus, that a brief one-session intervention delivered over a 60-90 minute period had the same effect as a two-session, total of four to five-hour intervention in decreasing sexual risk behavior is noteworthy because of feasibility. The shorter, less labor-intensive *MI* holds promise in resource-constrained settings, potentially having greater likelihood of being implemented in a non-research context.

Some limitations are noted. First, since intervention effects only were assessed over a five-month period, we are unable to determine whether they were maintained over a longer period and, therefore, we cannot rule out the possibility of differential longer-term effects between groups. Another limitation is that the study did not collect biomarkers of unprotected sex; rather, sexual behavior was self-reported via face-to-face interviews and therefore subject to social desirability reporting bias. This bias would likely be non-differential by intervention and would therefore reduce our ability to find a difference by intervention arm. We also did not have a non-intervention assessment-only group and therefore cannot rule out the possibility that neither intervention accounted for the observed results.

This research with university students in South Africa supports the value of a brief FC intervention. Many South African universities have health service delivery systems in place that can be mobilized to provide HIV prevention and support services, making them ideal

venues for promoting female and male condoms. Even with the above noted limitations, our findings may also have applicability for populations other than female university students. Introduction of a single group-based FC promotion intervention holds promise in a number of service delivery points in resource-constrained settings, and could easily be delivered in clinic waiting-rooms as well as in various community venues.

Interventions that promote female and male condom use are clearly needed in South Africa. The South African National HIV Survey found that overall condom use at last sex at the national level decreased from 45.1% in 2008 to 36.2% in 2012, with a higher percentage of males (38.6%) reporting that they had used a condom than females (33.6%); and among those who reported using condoms, use was inconsistent (27%) [20]. This decline in condom use has been accompanied by an increase in multiple sexual partnerships among men, thus highlighting omnipresent structurally-based gender inequalities that contribute to women's increased risk of HIV infection. Many women lack control over self-protection from HIV and other STIs because of gender inequities. Male partner resistance to prevention methods that interfere with their sexual pleasures makes it difficult for women to negotiate male condom use. Thus, promotion of methods that can be negotiated by women, such as the FC, to protect themselves from HIV infection needs to be accelerated [48, 49], highlighting the need for interventions targeted to both women and men.

## Conclusion

The FC is a highly under-utilized, effective HIV prevention method that has the potential to reduce HIV incidence among women and their partners as shown by a cost-effectiveness analysis in Brazil and South Africa [50]. Findings from a comprehensive national evaluation of South Africa's FC program currently underway [51] will elucidate key system, supply, partner, and user challenges to FC use, whereas the revitalization of South Africa's once thriving FC social marketing program will provide an opportunity for documenting FC demand through this distribution strategy and comparing it to public-sector demand. With greater global investment in both FC design to increase method acceptability and programming to increase product demand as well as implementation of interventions that can be easily replicated and do not drain resources, we may be able to maximize uptake and use of FCs.

## Acknowledgements


This research was supported by a grant from NICHD (NICHD; R01-HD046351; Joanne E. Mantell, M.S., MS.PH, Ph.D., Principal Investigator; Jennifer A. Smit, Ph.D., South Africa Site Principal Investigator). The HIV Center for Clinical and Behavioral Studies at the New York State Psychiatric Institute and Columbia University is supported by a center grant from the National Institute of Mental Health (P30-MH43520; Principal Investigator: Robert H. Remien, Ph.D.). We are grateful to the students who participated in this study and the valuable contributions of the study's Community Advisory Board. We also acknowledge the contributions of the officials at the higher education institution study site, who supported the study. The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Child Health and Human Development, the HIV Center for Clinical and Behavioral Studies at the New York State Psychiatric Institute and Columbia University, MatCH Research (Maternal and Adolescent Child Health Research), and the University of the Witwatersrand, Faculty of Health Sciences, Department of Obstetrics & Gynaecology.

## References

1. Reproductive Health Supplies Coalition. Caucus on new and underused reproductive health technologies. Product brief: female condom. Reproductive Health Supplies Coalition. 2012
2. Ahmed, K.; Deperthes, B.; Frederick, B.; Ehlers, S.; Kapp, N.; Paladines, C., et al. Contraceptive commodities for women's health working paper. UN Commission on Life-Saving Commodities for Women's and Children's Health; New York, NY: Mar. 2012 UN Commission on Life-Saving Commodities for Women and Children..
3. World Health Organization. Global HIV/AIDS response: Epidemic update and health sector progress towards universal access: Progress report 2011. World Health Organization; Geneva: 2011.
4. Fontanet AL, Saba J, Chandelying V, Sakondhavat C, Bhiraleus P, Rugsao S, et al. Protection against sexually transmitted diseases by granting sex workers in Thailand the choice of using the male or female condom: Results from a randomized controlled trial. *AIDS*. 1998; 12:1851–1859. [PubMed: 9792386]
5. French PP, Latka M, Gollub EL, Rogers C, Hoover DR, Stein ZA. Use-effectiveness of the female versus male condom in preventing sexually transmitted disease in women. *Sex Transm Dis*. 2003; 30:433–439. [PubMed: 12916135]
6. Hoke T, Feldblum P, Van Damme K, Nasution M, Grey T, Wong E, et al. Temporal trends in sexually transmitted infection prevalence and condom use following introduction of the female condom to Madagascar sex workers. *Int J STD AIDS*. 2007; 18:461–466. [PubMed: 17623503]
7. Artz L, Maculoso MM, Brill I, Kelaghan J, Austin H, Fleenor M, et al. Effectiveness of an intervention promoting the female condom to patients at sexually transmitted disease clinics. *American Journal of Public Health*. 2000; 90:237–244. [PubMed: 10667185]
8. Vijayakumar G, Mabude Z, Smit J, Beksinska M, Lurie M. A review of female-condom effectiveness: Patterns of use and impact on protected sex acts and STI incidence. *Int J STD AIDS*. 2006; 17:652–659. [PubMed: 17059633]
9. Gollub EL. The female condom: Tool for women's empowerment. *American Journal of Public Health*. 2000; 90:1377–1381. [PubMed: 10983187]
10. Peters A, Jansen W, Van Driel F. The female condom: The international denial of a strong potential. *Reprod Health Matters*. 2010; 18:119–128. [PubMed: 20541090]
11. Hoffman S, Mantell J, Exner T, Stein Z. The future of the female condom. *Perspectives on Sexual and Reproductive Health*. 2004; 36:120–126. [PubMed: 15306270]
12. United Nations Population Fund. HIV prevention gains momentum. UNFPA; New York, NY: 2011. 978-0-89714-933-4
13. Husken, S.; Terlikowski, J. Join the global movement for female condoms.. *Impatient Optimists*. In <http://www.impatientoptimists.org/Posts/2013/09/Join-the-Global-Movement-for-Female-Condoms> 2013 September 19
14. UNAIDS. Final Report. UNAIDS; Republic of South Africa. New York, NY: 2010. Country Progress Report on the Declaration of Commitment on HIV/AIDS..
15. Beksinska M, Smit J, Joanis C, Potter W. New female condoms in the pipeline. *Reprod Health Matters*. 2013; 20:188–196. [PubMed: 23245425]
16. Beksinska M, Smit J, Joanis C, Usher-Patel M, Potter W. Female condom technology: New products and regulatory issues. *Contraception*. 2011; 83:316–321. [PubMed: 21397088]
17. Beksinska M, Smit JA, Mantell JE. Progress and challenges to male and female condom use in South Africa. *Sex Health*. 2012; 9:51–58. [PubMed: 22348633]
18. Peterson, K.; Herman, L.; Marseille, E.; Kahn, JG. Smarter programming of the female condom: Increasing its impact on HIV prevention in the developing world. 2008. In [www.fsg-impact.org/app/content/ideas/item/Female\\_Condom\\_Impact.html](http://www.fsg-impact.org/app/content/ideas/item/Female_Condom_Impact.html): FSG Social Impact Advisors
19. Center for Health and Gender Equity (CHANGE). Female condoms and U.S. foreign assistance: An unfinished imperative for women's health. Center for Gender Equity and Health; Washington, DC: 2011.
20. Shisana, O.; Rehle, T.; Simbayi, LC.; Zuma, K.; Jooste, S.; Zungu, N., et al. South African National HIV Prevalence, Incidence and Behaviour Survey. HSRC Press; Cape Town, South Africa: 2014.

21. Pettifor, A.; Rees, H.; Steffenson, A.; Hlongwa-Madikizela, L.; MacPhail, C.; Vermaak, K., et al. HIV and sexual behaviour among young South Africans: National survey of 15-24 year olds. Reproductive Health Research Unit, University of the Witwatersrand; Johannesburg: 2004.
22. National Department of Health. National contraception and fertility planning policy and service delivery guidelines 2012. Department of Health; Pretoria, South Africa: 2013.
23. Department of Health. Republic of South Africa. National contraception and fertility planning policy and service delivery guidelines. Pretoria: Department of Health. 2012
24. MatCH (Maternal Adolescent and Child Health). Developing a strategy for female condom parallel programming: Proceedings of an expert meeting; Durban, South Africa. 23-24 November 2011; MatCH; 2011.
25. Guerra FM, Simbayi LC. Prevalence of knowledge and use of the female condom in South Africa. *AIDS and Behavior*. 2014; 18:146–158. [PubMed: 23934341]
26. Higher Education HIV/AIDS Programme (HEAIDS). HIV prevalence and related factors: Higher education sector study, South Africa, 2008-2009. Higher Education South Africa; Pretoria: 2010.
27. Ray S, van de Wijgert J, Mason P, Ndowa F, Maposhere C. Constraints faced by sex workers in use of female and male condoms for safer sex in urban Zimbabwe. *J Urban Health*. 2001; 78:581–592. [PubMed: 11796805]
28. van Devanter N, Gonzales V, Merzel C, Parikh NS, Celantano D, Greenberg J. Effect of an STD/HIV behavioral intervention on women's use of the female condom. *Am J Public Health*. 2002; 92:109–115. [PubMed: 11772772]
29. Witte SS, El-Bassel N, Gilbert L, Wu E, Chang M, Hill J. Promoting female condom use to heterosexual couples: Findings from a randomized clinical trial. *Perspect Sex Reprod Health*. 2006; 38:148–154. [PubMed: 16963388]
30. Kalichman SC, Williams E, Nachimson D. Brief behavioural skills building intervention for female controlled methods of STD-HIV prevention: Outcomes of a randomized clinical field trial. *Int J STD AIDS*. 1999; 10:174–181. [PubMed: 10340198]
31. Feldblum PJ, Kuyoh MA, Bwayo JJ, Omari M, Wong EL, Tweedy KG, et al. Female condom introduction and sexually transmitted infection prevalence: Results of a community intervention trial in Kenya. *AIDS*. 2001; 15:1037–1044. [PubMed: 11399986]
32. Choi KH, Hoff C, Gregorich SE, Grinstead O, Gomez C, Hussey W. The efficacy of female condom skills training in HIV risk reduction among women: A randomized controlled trial. *Am J Pub Health*. 2008; 98:1841–1848. [PubMed: 18703460]
33. Exner TM, Tesoriero JM, Battles HB, Hoffman S, Mantell JE, Correale J, et al. A randomized controlled trial to evaluate a structural intervention to promote the female condom in New York state. *AIDS Behav*. 2012; 16:1121–1132. [PubMed: 22484992]
34. Witte SS, El-Bassel N, Gilbert L, Wu E, Chang M, Hill J. Promoting female condom use to heterosexual couples: Findings from a randomized clinical trial. *Perspectives on Sexual and Reproductive Health*. 2006; 38:148–154. [PubMed: 16963388]
35. Feldblum PJ, Bwayo JJ, Kuyoh MA, Welsh MJ, Ryan KA, Chen-Mok M. The female condom and STDs: Design of a community intervention trial. *Ann Epidemiol*. 2000; 10:339–346. [PubMed: 10963999]
36. Malow R, Ziskind D, Jones DL. Use of female controlled microbicidal products for HIV risk reduction. *AIDS Care*. 2000; 12:581–588. [PubMed: 11218544]
37. Hoffman S, Exner TM, Leu CS, Ehrhardt AA, Stein ZA. Female condom use in a gender-specific family planning clinic trial. *Am J Public Health*. 2003; 93:1897–1903. [PubMed: 14600063]
38. Gollub EL, Cyrus-Cameron E, Armstrong K, Boney T, Chhatre S. Basic body knowledge in street-recruited, active drug-using women enrolled in a “body empowerment” intervention trial. *AIDS Care*. 2013; 25:732–737. [PubMed: 23216297]
39. Bandura, A. A social cognitive approach to the exercise of control over AIDS infection. Sage; Beverly Hills, CA: 1992.
40. Bandura, A. Social foundations of thought and action: A social cognitive theory. Prentice-Hall; Englewood Cliffs, NJ: 1986.

41. Ehrhardt AA, Exner TM, Hoffman S, Silberman I, Leu CS, Miller S, et al. A gender-specific HIV/STD risk reduction intervention for women in a health care setting: Short- and long-term results of a randomized clinical trial. *AIDS Care*. 2002; 14:147–161. [PubMed: 11940275]
42. Exner, TM.; Meyer-Bahlburg, HFL.; Yingling, SL.; Hoffman, S.; Ortiz-Torres, B. Psychosexual and psychosocial interviews for Project FIO (The Future is Ours). Columbia University, Department of Psychiatry; New York, NY: 1994. Unpublished
43. Harrison A, O'Sullivan LF, Hoffman S, Dolezal C, Morrell R. Gender role and relationship norms among young adults in South Africa: Measuring the context of masculinity and HIV risk. *J Urban Health*. 2006; 83:709–722. [PubMed: 16758334]
44. Rubin DB. Inference and missing data. *Biometrics*. 1976; 63:581–592.
45. Kamb ML, Fishbein M, Douglas JM Jr, Rhodes F, Rogers J, Bolan G, et al. Efficacy of risk-reduction counseling to prevent human immunodeficiency virus and sexually transmitted diseases: A randomized controlled trial. Project RESPECT Study Group. *JAMA*. 1998; 280:1161–1167. [PubMed: 9777816]
46. Mantell JE, Smit JA. Female condom use among South African students. National Institute of Child Health and Human Development. 2004-2010 R01-HD046351 unpublished data.
47. Mantell JE, Smit JA. HIV Prevention Efficacy Beliefs about Male Circumcision in South Africa American Foundation for AIDS Research (amfAR). 2008-2010 107200-44-RGRL unpublished data.
48. Mantell JE, Dworkin S, Exner TM, Hoffman S, Smit JA, Susser I. The promises and limitations of female-initiated methods of HIV/STI protection. *Social Science & Medicine*. 2006; 63:1998–2009. [PubMed: 16814912]
49. Mantell JE, Stein ZA, Susser I. Women in the time of AIDS: Barriers, bargains, and benefits. *AIDS Educ Prev*. 2008; 20:91–106. [PubMed: 18433316]
50. Dowdy DW, Sweat MD, Holtgrave DR. Country-wide distribution of the nitrile female condom (FC2) in Brazil and South Africa: A cost-effectiveness analysis. *AIDS*. 2006; 20:2091–2098. [PubMed: 17053355]
51. Beksinska M, Smit JA, Mabude Z, Mantell JE. Evaluation of the national South African female condom program: Investigating factors associated with uptake and sustained Use. USAIDPEPFAR Cooperative Agreement AID-OAA-A-13-00069.



**Figure 1.**  
Overview of study enrollment and flow



**Table 1**  
Baseline characteristics of sample by minimal and enhanced intervention conditions, female university students in South Africa

Variables	Minimal Intervention (N = 149)	Enhanced Intervention(N = 147)	Total (N = 296)	P <sup>a</sup>
Sociodemographic characteristics				
Main language Zulu, n (%)	120 (80.5%)	125 (85.0%)	245 (82.8%)	0.36
HIV/STIs				
Ever diagnosed with STI, n (%)	29 (19.9%)	26 (17.8%)	55 (18.8%)	0.77
Perceived chances of getting infected with HIV in next 6 months (range=1-4), mean(SD)	2.18 (0.86)	2.00 (0.89)	2.09 (0.88)	0.09
Condom Use for Contraception				
Ever used male condom, n (%)	145 (99.3%)	136 (95.8%)	281 (97.6%)	0.06
Ever used female condom, n (%)	4 (2.7%)	8 (5.6%)	12 (4.2%)	0.25
Ever used either male or female condom, n (%)	145 (99.3%)	137 (96.5%)	282 (97.9%)	0.12
Male or female condom use past 2 months, n (%)	105 (71.9%)	96 (68.1%)	201 (70%)	0.52
Male or female condom use last sex, n (%)	84 (56.8%)	75 (51.0%)	159 (53.9%)	0.35
Sexual Partners				
Number of sex partners lifetime (range = 1-20), mean (SD)	2.78 (2.29)	2.50 (2.16)	2.4 (2.3)	0.29
Has main male sex partner, n (%)	142 (95.3%)	140 (95.2%)	282 (95.3%)	1.00
Most recent main partner characteristics				
Age difference between participant and main partner, mean (SD)	3.77 (3.12)	3.26 (2.36)	3.52 (2.78)	0.13
Perceive main partner to be at risk for HIV and/or STI, n (%)	64 (45.4%)	60 (43.2%)	124 (44.3%)	0.72
Partner has had STI in last year, n (%)	10 (8.5%)	9 (7.6%)	19 (8.0%)	0.82

<sup>a</sup> t-tests and Chi-squared analyses were used to assess continuous and categorical variables, respectively; for two-by-two tables we report the Fisher exact two-sided p-value, and otherwise report Pearson p-values

**Table 2**

Sexual behavior variables: Regression models comparing baseline to each follow-up (2.5- & 5-months) within each intervention group (MI and EI)

	Minimal Intervention (1 Session)			Enhanced Intervention (2-Session)			
<i>Number of vaginal intercourse occasions unprotected by either male or female condoms<sup>a</sup></i>							
	<b>Mean</b>	<b>Rate Ratio</b>	<b>p-value</b>		<b>Mean</b>	<b>Rate Ratio</b>	<b>p-value</b>
Baseline	12.68	-	-	Baseline	7.10	-	-
FU1	6.75	0.53	0.02	FU1	2.29	0.41	<.0001
FU2	5.02	0.39	<.0001	FU2	2.24	0.40	<.0001
<i>Number of female condoms used<sup>a</sup></i>							
Baseline	0.02	-	-	Baseline	0.15	-	-
FU1	2.43	135.64	<.0001	FU1	2.40	16.78	<.001
FU2	1.04	57.97	<.0001	FU2	1.78	12.68	<.01
<i>Percentage of vaginal intercourse occasions protected by female condom<sup>b</sup></i>							
	<b>Mean</b>	<b>Mean difference</b>	<b>p-value</b>		<b>Mean</b>	<b>Mean difference</b>	<b>p-value</b>
Baseline	0.00	-	-	Baseline	0.01	-	-
FU1	0.15	0.15	<.0001	FU1	0.18	0.17	<.0001
FU2	0.08	0.08	<.0001	FU2	0.12	0.11	<.0001
<i>Percentage of vaginal intercourse occasions protected by female or male condom<sup>b</sup></i>							
Baseline	0.50	-	-	Baseline	0.48	-	-
FU1	0.79	.29	<.0001	FU1	0.85	.37	<.0001
FU2	0.75	.25	<.0001	FU2	0.82	.34	<.0001
<i>If used a female or male condom at the last sex occasion<sup>c</sup></i>							
	<b>% Yes</b>	<b>Odds Ratio</b>	<b>p-value</b>		<b>% Yes</b>	<b>Odds Ratio</b>	<b>p-value</b>
Baseline	56.80	-	-	Baseline	51.00	-	-
FU1	86.60	4.95	<.0001	FU1	82.00	4.35	<.0001
FU2	80.20	3.10	<.0001	FU2	86.00	5.93	<.0001
<i>Total number of vaginal intercourse occasions<sup>a</sup></i>							
	<b>Mean</b>	<b>Rate Ratio</b>	<b>p-value</b>		<b>Mean</b>	<b>Rate Ratio</b>	<b>p-value</b>
Baseline	23.75	-	-	Baseline	18.20	-	-
FU1	21.45	0.90	0.35	FU1	22.19	1.22	0.11
FU2	18.34	0.77	0.02	FU2	18.78	1.03	0.83
<i>If hormonal contraceptive use at the last sex occasion<sup>c</sup></i>							
	<b>% Yes</b>	<b>Odds Ratio</b>	<b>p-value</b>		<b>% Yes</b>	<b>Odds Ratio</b>	<b>p-value</b>
Baseline	12.50	-	-	Baseline	9.90	-	-
FU1	13.40	1.08	0.75	FU1	12.30	1.27	0.42
FU2	9.40	0.73	0.29	FU2	12.20	1.26	0.55

<sup>a</sup>Poisson regression model

<sup>b</sup>Linear regression model

<sup>c</sup>Logistic regression model

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

**Table 3**

Risk Perception: Regression models comparing baseline to each follow-up (2.5- & 5-months) within each intervention group (MI and EI)

	Minimal Intervention (1 Session)			Enhanced Intervention (2-Session)		
<i>Perceived risk of having an unintended pregnancy in the next 6 months<sup>b</sup></i>						
	Mean	Mean difference	p-value	Mean	Mean difference	p-value
Baseline	2.23	-	-	Baseline	2.02	-
FU1	1.75	-0.48	<.0001	FU1	1.69	-0.33
FU2	1.81	-0.42	<.0001	FU2	1.86	-0.16
						0.11 *
<i>Perceived risk of getting infected with HIV in the next 6 months<sup>b</sup></i>						
Baseline	2.18	-	-	Baseline	2.00	-
FU1	1.90	-0.28	0.01	FU1	1.64	-0.36
FU2	1.97	-0.21	0.01	FU2	1.75	-0.25
						<.01

\* Significant difference in change over time between the two interventions

<sup>b</sup> Linear regression model

**Table 4**

Condom use attitudes and norms: Regression models comparing baseline to each follow-up (2.5- & 5-months) within each intervention group (MI and EI)

	Minimal Intervention (1 Session)			Enhanced Intervention (2-Session)			
<i>Personal attitude about using the male condom<sup>b</sup></i>							
	<b>Mean</b>	<b>Mean Difference</b>	<b>p-value</b>		<b>Mean</b>	<b>Mean Difference</b>	<b>p-value</b>
Baseline	4.22	-	-	Baseline	4.35	-	-
FU1	4.43	0.26	0.01	FU1	4.48	0.13	0.10
FU2	4.45	0.23	0.01	FU2	4.49	0.14	0.09
<i>Perceived partner attitude toward male condom use<sup>b</sup></i>							
Baseline	3.53	-	-	Baseline	3.56	-	-
FU1	3.93	0.40	<.01	FU1	3.98	0.41	<.001
FU2	3.87	0.34	0.01	FU2	3.79	0.23	0.10
<i>Personal attitude toward female condom use<sup>b</sup></i>							
Baseline	2.97	-	-	Baseline	3.11	-	-
FU1	3.70	0.73	<.0001	FU1	3.96	0.85	<.0001
FU2	3.39	0.43	<.001	FU2	3.56	0.45	<.001
<i>Perceived partner attitude toward female condom use<sup>b</sup></i>							
Baseline	2.67	-	-	Baseline	2.63	-	-
FU1	2.92	0.25	0.05	FU1	2.89	0.27	0.03
FU2	2.88	0.21	0.10	FU2	2.94	0.31	0.02
<i>Peer norms for condom use<sup>b</sup></i>							
Baseline	2.76	-	-	Baseline	2.72	-	-
FU1	2.94	0.18	<.0001	FU1	3.03	0.31	<.0001 *
FU2	2.93	0.17	<.001	FU2	3.01	0.28	<.0001 *

\* Significant difference in change over time between the two interventions

<sup>b</sup> Linear regression model

**Table 5**

Condom use intention and self-efficacy: Regression models comparing baseline to each follow-up (2.5- & 5-months) within each intervention group (MI and EI)

	Minimal Intervention (1 Session)			Enhanced Intervention (2-Session)			
<i>Intention to use female condoms<sup>c</sup></i>							
	<b>Mean</b>	<b>Mean Difference</b>	<b>p-value</b>		<b>Mean</b>	<b>Mean Difference</b>	<b>p-value</b>
Baseline	2.28	-	-	Baseline	2.23	-	-
FU1	2.77	0.49	<.0001	FU1	2.77	0.54	<.0001
FU2	2.47	0.18	0.10	FU2	2.71	0.48	<.0001
<i>Condom use self-efficacy<sup>b</sup></i>							
Baseline	3.16	-	-	Baseline	3.21	-	-
FU1	3.56	0.39	<.0001	FU1	3.49	0.28	<.0001
FU2	3.46	0.29	<.0001	FU2	3.51	0.29	<.0001

<sup>b</sup>Linear regression model

<sup>c</sup>Logistic regression model